Moonlake Immunotherapeutics (MLTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,880 | -4,543 | -39,326 | -33,038 | -76 |
| Depreciation Amortization | 3 | N/A | 3 | 0 | N/A |
| Accounts receivable | -433 | N/A | -67 | -11 | N/A |
| Accounts payable and accrued liabilities | 2,247 | N/A | 763 | 549 | N/A |
| Other Working Capital | -379 | 3,959 | 3,482 | 1,227 | -14 |
| Other Operating Activity | 256 | -28 | 7,422 | 5,568 | -18 |
| Operating Cash Flow | $-14,186 | $-611 | $-27,723 | $-25,705 | $-108 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -16 | N/A | -32 | -21 | N/A |
| Investing Cash Flow | $-16 | $N/A | $-32 | $-21 | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 15,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | N/A | N/A | 107 | 107 | N/A |
| Other Financing Activity | 4 | -58 | 28,158 | 27,659 | -58 |
| Financing Cash Flow | $15,004 | $-58 | $28,264 | $27,766 | $-58 |
| Exchange Rate Effect | -7 | N/A | -1 | N/A | N/A |
| Beginning Cash Position | 8,039 | 1,336 | N/A | N/A | 1,336 |
| End Cash Position | 8,834 | 667 | 508 | 2,041 | 1,170 |
| Net Cash Flow | $795 | $-669 | $508 | $2,041 | $-166 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,186 | -611 | -27,723 | -25,705 | -108 |
| Capital Expenditure | -16 | N/A | -32 | -21 | N/A |
| Free Cash Flow | -14,202 | -611 | -27,756 | -25,725 | -108 |